1 min read

COO of Abveris, Tracey Mullen, to Present at Antibody Engineering 2019 in San Diego

By Travis LeGuyader on 12/3/19 1:49 PM

December 9, 2019 – San Diego, CA - Are you attending the upcoming Antibody Engineering and Therapeutics conference in San Diego on December 9th? It’s not too late to sign up and spend some time in the sun while staying updated on the latest antibody discovery technologies and engineering techniques while networking with lead scientists in the antibody discovery world.

Join us on December 12 at noon for a scientific briefing led by Tracey Mullen, our Chief Operating Officer. Or, stop by our booth or posters in the exhibit hall and meet with Garren (CEO), Ryan (Director of Business Development) and Travis (Business Development Associate). See you there!

Click here to schedule an appointment with our team at the conference.


Information on our Scientific Briefing:
Scientific Briefing: Antibody Discovery for Traditionally Difficult Targets: in vivo, in vitro, or both?

Abstract: Leveraging the natural immune repertoire for antibody discovery has distinct advantages for positive downstream outcomes, including efficacy, developability and safety; however, traditional techniques typically fail to produce a productive response in situations where, for example, the target epitope has poor immunogenicity or is a rare, cryptic site. While some in vitro platforms can overcome these difficulties through careful guiding selection methods, significant downstream engineering is often required to ensure lead candidates harbor appropriate development qualities. Fortunately, recent advancements in protein engineering and antibody discovery have enabled improved drug development to these traditionally difficult targets. Using the AbX platform, the power of the immune system is harnessed to exemplify the breadth and comprehensive nature of the B cell repertoire. When applied to the most difficult target classes, lead candidates can be uncovered where traditional in vivo platforms typically fail, or significant engineering is required for in vitro discovery.

About the Antibody Engineering Conference: Antibody Engineering is the #1 antibody engineering conference for accelerating next-generation antibodies to commercial success. Find the latest science, technology, and partners in antibody engineering, immunobiology, and next-generation binders.


Antibody Engineering Logo


Topics: Conferences
1 min read

Abveris to attend Festival of Biologics 2019 in Basel, Switzerland

By Matthew Bartolucci on 10/3/19 10:17 PM

Basel, CH - October 4, 2019 - Will you be at the Festival of Biologics conference in Switzerland this year? Meet with our Director of Business Development, Ryan Kelly, who will be presenting a posters about our proprietary therapeutic antibody discovery technologies.  See you there from October 15-17.

About Festival of Biologics:

The Festival of Biologics combines four outstanding conferences, the European Antibody Congress, the World Immunotherapy Congress, the World Biosimilar Congress and the Clinical Trials World Congress to make one amazing event.

With both a conference and exhibition, the show brings together industry leaders to meet, discuss and showcase their work in the biologics, biopharma and immunotherapy fields, just to name a few.

The Congress hosts high-level speakers hailing from big pharma, biotech, academia, regulatory bodies, investor groups, and associations, discussing topics representing key challenges within their industries, new data, case studies and research.

This year, presentations will move through the entire development pipeline and focus on commercial applications. The Festival of Biologics’ mission is to bring together the full value chains from the antibodies, immunotherapy, clinical trials and biosimilars industries together, located in Basel – a major life science hub.

Topics: Conferences
1 min read

CSO of Abveris, Colby Souders, Ph.D., to Present at Discovery On Target 2019

By Ryan Kelly on 8/22/19 9:07 AM

August 22, 2019 – Boston, MA – Representatives from Abveris will attend the 17th Annual Discovery On Target Conference, September 16-19, 2019, in Boston, MA. Colby Souders, Chief Scientific Officer of Abveris, will serve as chairperson for the Antibody Engineering and Development Forum and present "Screening Tools for Early Prediction of Development and Clinical Success" at 3:40PM on Thursday, September 19. An abstract for the presentation is listed below.

Click here to schedule an appointment with the Abveris team during the conference.

As industry-wide advancements in antibody drug discovery continue to push toward larger panels of candidates for early-stage antibody characterization, more efficient identification of lead molecules through enhanced screening resolution is required. Integrating tools and methods into the overall characterization workflow enables reliable, high throughput selection of lead candidates more effectively than alternative traditional techniques. Comparisons across platforms, including traditional ELISA, flow cytometry, Octet and in vivo studies will be presented that provide enhanced prediction of downstream development and clinical success.

About Discovery On Target:

The 17th Annual Discovery on Target (DOT), the industry’s preeminent event on novel drug targets and technologies, will convene over 1,300 drug discovery professionals in Boston, MA, on September 16-19, 2019. This event highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules.

Topics: Team Updates Conferences
1 min read

Abveris to speak at the Future of Drug Discovery and Development Symposium

By Matthew Bartolucci on 6/11/19 10:35 AM

Boston, MA - June 11, 2019 - Ryan Kelly, the Associate Director of Business Development at Abveris, will give a talk about our advanced immunization strategies and antibody discovery platform technologies at the Future of Drug Discovery and Development Symposium hosted by ACROBiosystems and Biocytogen.

The symposium will be held on Thursday June 13, 2019 from 1-6PM in Cambridge.

Register for free to attend the symposium on Eventbrite.

Join the symposium to learn more about cutting-edge therapeutic antibody discovery technologies and the latest research in biologics drug development. The conference is free to attend, light refreshments and dinner will be provided.

Confirmed Speakers:

Chun-Nan Chen

CEO and CSO, Single Cell Technology

Qingcong Lin

CEO, Biocytogen Boston Corp

Stephen Gillies

CSO, LinkedUp Bioscience Inc

Johanna Lahdenranta

Director of In Vivo Pharmacology, Bicycle Therapeutics

Ryan Kelly

Associate Director, BD at Abveris, Co-Founder at AbX Biologics

Xiaodong Li

Associate of Patent and Intellectual Property, Choate, Hall & Stewart LLP


Click here to learn more about the symposium.

Event Details & Address:

Thursday June 13, 2019 from 1-6PM

Residence Inn Boston Cambridge

120 Broadway, Six Cambridge Center

Cambridge, MA

Topics: Conferences
1 min read

Abveris to attend the PEGS Boston Protein Engineering Summit

By Ryan Kelly on 3/24/19 12:05 PM

Boston, MA - March 24, 2019 - Will you be at PEGS Boston this year? Come visit us in the exhibit hall at Booth #518. In addition to our exhibit, scientists from Abveris will be presenting two posters about our proprietary mouse technology and our anti-idiotype antibody discovery process.  See you there from April 8th - 12th.

About PEGS Boston:

PEGS: The Essential Protein Engineering Summit is the industry’s preeminent event that inspires innovative biotherapeutic protein drug development.

The PEGS Summit has celebrated record growth for ten consecutive years with over 2,600 industry professionals in attendance and is on track to set another new record this spring.

PEGS Boston 2019 will host more than 400 lectures, panels, tutorials and round-table discussions, along with 150+ exhibitors, and 300 research posters on display in the exhibit hall. The speaker lineup includes world-renowned experts, visionaries, and influencers from top pharma, biotech, academic, and government institutions.

Topics: Conferences